Kronos Bio Ends Collaboration with Genentech and Roche
I'm PortAI, I can summarize articles.
Kronos Bio, Inc. has ended its collaboration with Genentech and Roche by entering a Transition Agreement. This agreement allows Kronos Bio to transfer all small molecule compounds, materials, data, and intellectual property from their joint research programs to Genentech while retaining its proprietary drug discovery platform. The deal includes a perpetual license for Genentech, cancels downstream payment obligations, and involves a one-time payment from Kronos Bio to facilitate the transition. Kronos Bio focuses on developing novel cancer therapies and currently has a market cap of $55.51M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments